Partnering and Business Opportunities

There are numerous SPARK projects open for partnering and business opportunities. Explore the projects below and get in touch.


Anti-Infective

  • sk05029
    Novel aminoglycoside antibiotic based on new understanding of ototoxicity. Leads show broad-spectrum antimicrobial activity and substantially less ototoxicity and nephrotoxicity in animals.
  • sk10121
    Novel broadly-protective influenza vaccine. Currently optimizing protein folding and developing a cold-chain independent production scheme. Plan ferret testing within a year.

Cardiovascular

  • sk09111
    Novel target to treat heart failure through agonist activity. Proof-of-concept animal studies supported link between target signaling and cardiac function.

Dermatology

  • sk07081
    Small molecule inducer of melanin production/tanning response as therapy for xeroderma pigmentosum (XP), vitiligo, erythropoietic protoporphyria (EPP). 

Gene therapy

  • sk10134
    Innovative platform to enhance Adeno-associated virus (AAV)-based gene therapy. Identified a host factor to improve AAV infection for all serotypes and cell types.

Immunology/Hematology

  • sk08095
    Combination therapeutic monoclonal antibody plus engineered immune cells to treat acute gastrointestinal graft versus host disease (GVHD) (orphan disease).

Metabolic

  • sk08096 
    Small molecule inducer of beta cell regeneration for treatment of type 2 diabetes. Lead compound optimization on-going.
  • sk08091
    Novel targets for induction of brown fat from white fat to treat obesity. Preparing high-throughput screening to identify small molecule inhibitors.

Oncology

  • sk09105
    Repurposed small molecule to prevent cancer emergence in patients with inherited BRCA-1 mutants (orphan disease). Establishing biomarkers and in consultation with FDA about trial endpoints. Good drug safety record, but never approved in USA.
  • sk10128
    Topical formulation of a small molecule plant extract to prevent radiation dermatitis, salivary indications and possibly dry eyes during cancer treatment. Currently in preclinical testing.

Platform

  • sk12158
    Charge –Altering Releasable Transporters (CARTS): New materials enable a new platform technology for gene delivery, vaccinations, and cancer immunotherapy